Dr. [Name] Obituary: Insulin Equity Advocate & Global Health Pioneer (1943-2025)

The world of global health has lost a dedicated advocate with the passing of Dr. John Yudkin, who died in north London on December 17, 2025, at the age of 82. A physician by training, Dr. Yudkin devoted his career to campaigning for equitable access to insulin, a life-saving medication for millions living with diabetes, and to training a new generation of clinicians focused on global health challenges.

The Insulin Access Crisis: A Legacy of Advocacy

Dr. Yudkin’s work came at a critical time. As highlighted in a 2021 report by the World Health Organization (WHO), access to insulin remains alarmingly uneven globally. The report, published in the lead-up to World Diabetes Day, identifies high prices, limited availability of human insulin, a concentrated market dominated by a few producers, and weak health systems as key barriers to universal access. The WHO report notes the historical irony that the scientists who discovered insulin a century ago deliberately chose not to profit from their breakthrough, selling the patent for just one dollar – a stark contrast to the current multi-billion-dollar insulin market.

Dr. Yudkin’s commitment stemmed from a deep understanding of the devastating consequences of untreated diabetes. Insulin is not merely a treatment for type 1 diabetes, affecting nine million people worldwide; it’s also essential for over 60 million people with type 2 diabetes, significantly reducing the risk of kidney failure, blindness, and limb amputation. Yet, the WHO estimates that half of those needing insulin for type 2 diabetes do not receive it. This disparity is particularly acute in low- and middle-income countries, where the burden of diabetes is rising rapidly, but insulin consumption hasn’t kept pace.

Beyond Insulin: A Focus on Global Health Capacity

Dr. Yudkin’s influence extended beyond direct advocacy for insulin access. He recognized that sustainable solutions required a robust global health workforce. He dedicated a significant portion of his career to training clinicians, equipping them with the skills and knowledge to address health inequities in their own communities. While details of his specific training programs are not widely available, his focus on capacity building reflects a broader understanding that access to medication is only one piece of the puzzle. Effective healthcare systems, skilled personnel, and strong public health infrastructure are equally crucial.

The Pan American Health Organization (PAHO), the WHO Regional Office for the Americas, echoes this sentiment. PAHO’s statement accompanying the WHO report highlights the growing prevalence of diabetes in the Americas – tripling since 1980 to an estimated 62 million adults – and the corresponding need for increased access to insulin and comprehensive diabetes care.

The Shift to Insulin Analogues and its Implications

A key aspect of the insulin access challenge, as identified by the WHO, is the global market shift from human insulin – which can be produced relatively inexpensively – to pricier insulin analogues (synthetic insulins). This transition places an unsustainable financial burden on lower-income countries, exacerbating existing inequities. The report points out that while the majority of people with type 2 diabetes reside outside of North America and Europe, they account for less than 40% of global insulin sales revenue. This imbalance underscores the need for more equitable pricing and distribution models.

The complexities of insulin production and distribution are further compounded by the limited number of manufacturers dominating the market. This concentration of power can lead to price manipulation and supply disruptions, hindering access for vulnerable populations. Addressing these systemic issues requires collaborative efforts between governments, manufacturers, and international organizations like the WHO.

What Comes Next: A Continuing Call for Action

Dr. Yudkin’s passing serves as a poignant reminder of the ongoing struggle for equitable access to essential medicines. His legacy will undoubtedly inspire continued advocacy and innovation in the field of global health. The WHO is actively working with countries and manufacturers to address the barriers to insulin access, but sustained commitment and investment are essential.

Looking ahead, several key areas require attention. Continued monitoring of insulin prices and availability is crucial, as is the promotion of generic insulin production to increase competition and lower costs. Strengthening health systems in low- and middle-income countries is paramount, ensuring that individuals with diabetes receive not only insulin but also the necessary education, monitoring, and support to manage their condition effectively. Further research is needed to understand the specific barriers to insulin access in different regions and to develop tailored interventions to address them. Further details on the WHO report can be found on the National Center for Biotechnology Information website.

The fight for universal access to insulin, and to healthcare more broadly, is a long-term endeavor. Dr. John Yudkin’s dedication to this cause will be deeply missed, but his work will continue to resonate, urging us to strive for a world where life-saving medicines are available to all who need them.